Male Infertility Drug Pipeline — PatSnap Eureka
Male Infertility Drug Pipeline: FSH, Antioxidants & Spermatogenesis Stimulators
Male factor infertility contributes to 40–50% of infertile couples globally, yet most men are managed empirically. Explore the full pipeline — from FSH biologics and antioxidant RCTs to RANKL antagonism and spermatogonial stem cell therapies — powered by PatSnap Eureka patent and literature intelligence.
Three Pathobiological Axes Driving Male Infertility Drug Development
Male factor infertility is responsible for approximately 20–50% of infertility cases worldwide, affecting an estimated 8–12% of reproductive-age men. Among clinically characterized etiologies, oligoasthenoteratozoospermia (OAT) accounts for approximately 90% of male infertility presentations, with idiopathic cases comprising 25–80% of that burden depending on the cohort. The World Health Organization recognizes male infertility as a major global reproductive health challenge.
Oxidative stress, gonadotropin dysregulation, and spermatogenesis failure are the three dominant pathobiological axes driving current drug development activity. A meta-analysis encompassing 3,819 infertility patients and 2,012 controls confirms significantly elevated malondialdehyde (MDA, SMD = 1.86) and carbonyl protein (SMD = 2.09), and depressed catalase (SMD = −1.91) and glutathione peroxidase activities in infertile men.
The FSH-FSHR signaling axis through Sertoli cells is identified as the primary pharmacologically actionable hormonal target for normogonadotropic idiopathic infertility. Inhibin B shows a strong correlation (r = 0.74, p < 0.001) with sperm count, validating it as a spermatogenesis biomarker. Researchers at PatSnap's life sciences platform track these targets across global patent filings and clinical literature.
Emerging molecular targets include the RANKL/RANK germ cell apoptosis axis, the miR-210/IGF2 axis in non-obstructive azoospermia (NOA), and the FST/Inhba (follistatin/inhibin beta-A) axis modulated by small molecules such as Schisandrin B. For RNA-based intervention target intelligence, the NIH PubMed database provides foundational literature access.
Quantifying the Evidence: Oxidative Stress & FSH Therapy
Key data points from patent and literature analysis, visualized from meta-analytic and clinical trial evidence in the retrieved dataset.
Oxidative Stress Biomarker Elevation in Infertile Men (SMD)
Meta-analysis of 65 studies (3,819 patients, 2,012 controls) shows significantly elevated pro-oxidant markers and depressed antioxidant enzymes in infertile men vs. normozoospermic controls.
Ashwagandha Pilot RCT: Sperm Parameter Improvements (90 Days, 46 Men)
A double-blind pilot RCT in 46 oligospermic men showed 167% increase in sperm count, 57% increase in motility, and 53% increase in semen volume after 90 days of Withania somnifera supplementation.
FSH Therapy Pregnancy Outcomes: Meta-Analysis Evidence (614 Men)
Meta-analysis of 15 controlled studies shows FSH therapy achieves OR 4.5 for spontaneous pregnancy and OR 1.60 for ART pregnancy versus controls in idiopathic normogonadotropic infertility.
Pipeline Maturity by Therapeutic Modality
Distribution of evidence maturity across retrieved pipeline modalities, from preclinical small molecules to clinical-stage FSH and antioxidant RCTs.
Seven Therapeutic Approaches in the Male Infertility Pipeline
From clinically validated FSH biologics to emerging cell therapies and traditional medicine-derived small molecules — the pipeline spans a wide evidence spectrum.
FSH-Based Hormonal Stimulation
FSH is the most clinically established pharmacological intervention for idiopathic male infertility. A meta-analysis of 15 controlled studies (614 FSH-treated men, 661 controls) reported a spontaneous pregnancy odds ratio of approximately 4.5 (CI: 2.17–9.33) and an ART pregnancy OR of 1.60 (CI: 1.08–2.37). FSH preparations studied include recombinant follitropin-α, follitropin-β, and urofollitropin, with differential in vitro effects on Sertoli cell AMH and inhibin B production. Testosterone serum levels have been identified as a predictive biomarker for sperm DNA fragmentation improvement following FSH therapy, analyzed across 251 patients in three trials. PatSnap's analytics platform tracks FSH patent filings globally.
OR 4.5 spontaneous pregnancy · 15 controlled studiesAntioxidant Supplementation
The largest cluster of retrieved results addresses antioxidant supplementation as empirical therapy for idiopathic OAT. Compounds evaluated include SOD, glutathione, selenium, zinc, vitamins C and E, CoQ10, L-carnitine, L-acetylcarnitine, resveratrol, alpha-lipoic acid, NAC, myo-inositol, folate, and pyridoxine. A double-blind trial of L-carnitine plus L-acetylcarnitine (Proxeed Plus) in 175 oligoasthenozoospermic men showed significant improvements in sperm volume, progressive motility, and vitality. Antioxidant treatment activates oxidative phosphorylation and upregulates 274 proteins involved in spermatogenesis, sperm maturation, and fertilization (379 differentially expressed proteins total). The NIH maintains active funding for antioxidant reproductive trials.
175 men · Proxeed Plus RCT · 379 differentially expressed proteinsNatural Compound Spermatogenesis Stimulators
Beyond classical antioxidants, several small molecules show direct spermatogenesis-stimulating activity. Schisandrin B (from the Wuzi Yanzong Pill) modulated 2,033 testicular genes via the FST/Inhba pathway and improved sperm count and mobility in oligoasthenospermia mice (Peking University). D-Aspartate at 20 mM improved fertilizing capability in male C57BL/6N mice. IGF-1 intradermal administration (1.5 IU/day, 2 months) produced a 15.5-fold improvement in sperm concentration in a severe OAT case report. Mucuna pruriens/L-DOPA restored spermatogenesis in a rat estrogen-suppression model by combating ROS and recovering mitochondrial membrane potential. Explore these compounds through PatSnap's chemical intelligence tools.
2,033 genes modulated · Schisandrin B · 15.5× sperm concentration (IGF-1 case)RANKL Pathway Antagonism (Denosumab)
A patent from Rigshospitalet (EP, 2019, active) discloses anti-RANKL antibodies — including denosumab — as novel therapeutics for male infertility. The mechanistic rationale involves RANKL/OPGbp–RANK regulation of germ cell proliferation and apoptosis. The FITMI study, a double-blinded placebo-controlled RCT, has been designed to evaluate a single-dose denosumab in infertile men selected by serum AMH as a predictive biomarker. This represents the only retrieved biologic/antibody-based approach with an active patent and an ongoing clinical trial design — and the most novel precision medicine approach in this dataset. The EMA regulates denosumab's existing oncology indications.
EP 2019 active patent · FITMI RCT · AMH biomarker selectionSpermatogonial Stem Cell (SSC) Therapies
SSC transplantation and in vitro spermatogenesis are regenerative approaches for NOA and chemotherapy-induced infertility. The full scope of SSC therapies — including autologous transplantation, in vitro maturation, and testicular tissue grafting — is reviewed from the University of British Columbia and Beni-Suef University. Cytokines and hormones including testosterone and FSH support SSC differentiation in chemotherapy-treated immature mice (Ben-Gurion University of the Negev). SSC transplantation remains preclinical to translational in retrieved evidence and is unlikely to be displaced by small molecules for NOA patients in the near term.
NOA · Oncofertility · Preclinical–TranslationalMSC Secretome & Testosterone Replacement Modulation
A novel approach from Lomonosov Moscow State University identifies intratesticular injection of MSC secretome as a spermatogenesis-restoring strategy for idiopathic male infertility, with VEGF identified as a potency marker for treatment response. Separately, conversion from long-acting testosterone replacement therapy (TRT) to short-acting intranasal testosterone (Natesto) is documented as a strategy to resume spermatogenesis in hypogonadal men (27-patient proof-of-concept study). Human chorionic gonadotropin (hCG), clomiphene, and selective estrogen receptor modulators are also characterized as hormonal tools for managing anabolic steroid-induced infertility.
VEGF potency marker · Natesto · 27-patient proof-of-conceptKey Compounds, Assignees & Development Stage
Retrieved patent and literature records mapped to compound, target, institution, and evidence stage. PatSnap tracks active filings across all modalities.
| Compound / Approach | Target / Mechanism | Lead Institution | Evidence Stage | IP Status |
|---|---|---|---|---|
| Recombinant FSH (follitropin-α/β, urofollitropin) | FSHR / Sertoli cell axis | University of Modena, Italy | Clinical / RCT | Established biologics |
| L-Carnitine + L-Acetylcarnitine (Proxeed Plus) | Oxidative stress / mitochondrial function | Sigma-tau Health Science | Clinical / RCT | Nutraceutical commercial |
| FH PRO for Men (multi-antioxidant) | ROS / ORP / SDF reduction | Hamad General Hospital | Clinical | Commercial formulation |
| Denosumab (anti-RANKL) | RANKL/RANK germ cell apoptosis | Rigshospitalet, Denmark | Early Clinical (FITMI RCT) | EP 2019 active patent |
| Schisandrin B | FST/Inhba axis · 2,033 testicular genes | Peking University, China | Preclinical | Academic publication 2020 |
Track Assignees & Active Patents in Real Time
Rigshospitalet, Mastelli S.r.l., Sigma-tau, Peking University — monitor divisional filings and method-of-treatment claims as they publish.
What the Pipeline Signals for IP Strategy & Drug Development
Key strategic takeaways derived from patent and literature evidence in the retrieved dataset.
FSH Remains the Most Validated Target
FSH is the most clinically validated pharmacological target, with meta-analytic evidence supporting its use in idiopathic normogonadotropic infertility. Drug developers should consider FSH receptor-targeted allosteric modulators or chimeric gonadotropins as next-generation alternatives to injectable FSH, improving patient compliance and dosing flexibility.
Antioxidant IP Is a Contested Commercial Space
Antioxidant formulation IP is a contested commercial space with multiple nutraceutical products on the Italian and global markets. Retrieved systematic evaluations find only 12.5% of marketed dietary supplements in high expected-efficacy classes — a quality gap and commercial opportunity for IP-protected, efficacy-validated fixed-dose combinations including SOD, L-carnitine, CoQ10, selenium, and inositol at minimum effective daily doses.
RANKL/Denosumab: Most Novel Biologic Target
The RANKL/denosumab axis is the most novel clinically testable biologic target in this dataset, backed by an active EP patent (Rigshospitalet) and a registered RCT. IP strategists should monitor this space for divisional filings and method-of-treatment claims covering AMH-selected patient populations.
miRNA: Greenfield IP Space for RNA Drug Platforms
miRNA-based diagnostics and potential therapeutics (miR-210/IGF2; miR-19a/b-3p; miR-34b for oligozoospermia) are currently at the biomarker identification stage but represent a greenfield IP space for therapeutic oligonucleotide developers, particularly those with existing RNA drug platforms seeking reproductive medicine indications.
Combination Approaches & Next-Generation Strategies
Retrieved results signal several combination and emerging strategies that go beyond single-agent therapy. A Siena University study evaluating a nutraceutical formulation containing inositol, L-carnitine, vitamins C/D/E, CoQ10, and selenium — described as combining antioxidants with "natural hormone stimulants" — demonstrated improved sperm concentration and IVF outcomes in OAT patients. This signals a trend toward multi-ingredient formulations targeting both oxidative and endocrine pathways simultaneously.
In vitro data from the International Scientific Institute Paul VI (Rome) demonstrate that combining FSH preparations with testosterone produces differential Sertoli cell proteomic responses, with follitropin-α uniquely activating specific protein sets. This points toward individualized FSH formulation selection based on patient FSH receptor polymorphism or testosterone background — a precision medicine approach supported by PatSnap's analytics platform.
The FITMI trial protocol signals use of AMH as an enrichment biomarker to identify patients most likely to respond to RANKL inhibition — representing a precision medicine approach to male infertility therapeutics. VEGF-containing MSC secretome therapy targeting the testicular microenvironment represents a novel regenerative direction for idiopathic infertility unresponsive to conventional hormonal treatments, at the IND-enabling or early proof-of-concept stage. For regulatory pathway intelligence, the FDA provides guidance on IND applications for cell-based therapies. PatSnap customers in reproductive medicine actively track these emerging clinical signals.
Retrieved data highlighting miR-210/IGF2 and miR-19a/b-3p axes in NOA and oligoasthenozoospermia suggest potential for small RNA-based therapeutic intervention, though no retrieved patent or clinical protocol yet addresses this angle directly — representing a greenfield IP opportunity. The WIPO patent database can be used to monitor emerging RNA therapeutic filings in this space.
Male Infertility Drug Pipeline — key questions answered
Male factor infertility is responsible for approximately 20–50% of infertility cases worldwide, affecting an estimated 8–12% of reproductive-age men. Among clinically characterized etiologies, oligoasthenoteratozoospermia (OAT) accounts for approximately 90% of male infertility presentations, with idiopathic cases comprising 25–80% of that burden depending on the cohort.
A meta-analysis encompassing 15 controlled studies (614 FSH-treated men, 661 controls) reported a spontaneous pregnancy odds ratio of approximately 4.5 (CI: 2.17–9.33) and a significant ART pregnancy OR of 1.60 (CI: 1.08–2.37). A separate meta-analysis of randomized controlled trials confirmed FSH efficacy on sperm concentration, total count, and progressive motility, with dose-response data spanning 175–262.5 IU/week low-dose and higher regimens.
Compounds evaluated include superoxide dismutase (SOD), glutathione (GSH), selenium, zinc, vitamin C, vitamin E, coenzyme Q10 (CoQ10), L-carnitine, L-acetylcarnitine, resveratrol, alpha-lipoic acid, N-acetylcysteine (NAC), myo-inositol, folate, and pyridoxine. A randomized double-blind trial of L-carnitine plus L-acetylcarnitine (Proxeed Plus) in 175 oligoasthenozoospermic men showed significant improvements in sperm volume, progressive motility, and vitality.
A patent from Rigshospitalet (EP, 2019, active) discloses anti-RANKL antibodies — including denosumab — as novel therapeutics for male infertility. The mechanistic rationale involves RANKL/OPGbp–RANK regulation of germ cell proliferation and apoptosis. The FITMI study, a double-blinded placebo-controlled RCT, has been designed to evaluate a single-dose denosumab in infertile men selected by serum AMH as a predictive biomarker.
A pilot RCT in 46 oligospermic men demonstrated a 167% increase in sperm count, 53% increase in semen volume, and 57% increase in sperm motility after 90 days of Ashwagandha (Withania somnifera) supplementation.
SSC transplantation and in vitro spermatogenesis are regenerative approaches for non-obstructive azoospermia (NOA) and chemotherapy-induced infertility. SSC transplantation in mouse models to repopulate depleted testes has been reviewed, and the full scope of SSC therapies — including autologous transplantation, in vitro maturation, and testicular tissue grafting — is documented. SSC transplantation remains preclinical to translational in retrieved evidence.
Still have questions? Let PatSnap Eureka search the patent and literature evidence for you.
Ask Eureka About the PipelineAccelerate Your Male Infertility Drug Research
Join 18,000+ innovators already using PatSnap Eureka to map therapeutic targets, track assignees, and identify IP white space in reproductive medicine.
References
- Antioxidant Intervention against Male Infertility: Time to Design Novel Strategies — University of Chile, 2022
- Is male infertility associated with increased oxidative stress in seminal plasma? A meta-analysis — Sichuan Agricultural University, 2018
- In vitro Effect of Different Follicle-Stimulating Hormone Preparations on Sertoli Cells — International Scientific Institute Paul VI, Rome, 2020
- FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis — Unit of Endocrinology, Modena, 2015
- Inhibin-B and FSH Are Good Indicators of Spermatogenesis but Not the Best Indicators of Fertility — Centre of Postgraduate Medical Education, Warsaw, 2022
- Antibodies, compounds and derivatives thereof for use in the treatment of male infertility — Rigshospitalet, EP, 2019 [Patent]
- Up-Regulation of microRNA-210 is Associated with Spermatogenesis by Targeting IGF2 in Male Infertility — First Affiliated Hospital of Anhui Medical University, 2016
- Schisandrin B for treatment of male infertility — Peking University, 2020
- Spermatogonial stem cell transplantation and male infertility: Current status and future directions — University of British Columbia, 2018
- Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia — Beni-Suef University, 2021
- FSH dosage effect on conventional sperm parameters: a meta-analysis of randomized controlled studies — University of Catania, 2020
- FSH for the Treatment of Male Infertility — University of Modena, 2020
- Testosterone Serum Levels Are Related to Sperm DNA Fragmentation Index Reduction after FSH Administration — Azienda Ospedaliero-Universitaria di Modena, 2022
- Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters — Sigma-tau Health Science, 2019
- Clinical Evaluation of the Spermatogenic Activity of Ashwagandha Root Extract in Oligospermic Males — Mahalaxmi Clinic, Mumbai, 2013
- Wuzi Yanzong Pill Protects Against Spermatogenesis Disorder via Regulation of the Apoptosis Pathway — Zhejiang Chinese Medical University, 2020
- Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study) — Harvard University, 2022
- World Health Organization — Reproductive Health and Research
- National Institutes of Health — Reproductive Medicine Research
- WIPO — World Intellectual Property Organization Patent Database
- European Medicines Agency — Denosumab Regulatory Information
- U.S. Food and Drug Administration — Cell-Based Therapy IND Guidance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.